Last edited by Kagajinn
Wednesday, July 15, 2020 | History

2 edition of Consensus Development Conference on the Management of Clinically Localized Prostate Cancer found in the catalog.

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer (1987 Bethesda (Md.))

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer

National Institutes of Health, Bethesda, Maryland, June 15-17 1987.

by Consensus Development Conference on the Management of Clinically Localized Prostate Cancer (1987 Bethesda (Md.))

  • 279 Want to read
  • 14 Currently reading

Published by National Cancer Institute in Bethesda (Md.) .
Written in English


Edition Notes

At head of title : National Institutes of Health.

Other titlesManagement of clinically localized prostate cancer.
SeriesNCI monographs -- 7, 1988, NIH publication -- 88-3005
ContributionsNational Cancer Institute.
The Physical Object
Pagination175p. :
Number of Pages175
ID Numbers
Open LibraryOL14254527M

Book: AHRQ Review. Preventing Violence and Related Health-Risking Social Behaviors in Adolescents:an NIH State-of-the-Science Conference: 1, 2, 3, 3a: News Release: P&A Book: AHRQ Review. NIH Consensus Development Conference on Celiac Disease: 1, 2, or 3: News Release: P&A Book: AHRQ Review.   Spratt DE, Zhang J, Santiago-Jiḿenez M, Dess RT, Davis JW, Den RB, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate.

At the consensus conference, 71 experts from the United States, Canada, England, and the Netherlands anonymously responded to a series of clinical questions centered on the management of. The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who.

  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Recently, there has been increasing interest in methodological aspects of advanced imaging, including the role of guidelines, recommendations, and experts’ consensus, the practice of self-referral, and the risk of diagnostic procedure overuse. In a recent Delphi study of the European Association for Nuclear Medicine (EANM), panelists were asked to give their opinion on 47 scientific.


Share this book
You might also like
control of inflation

control of inflation

Katharsis

Katharsis

See How Its Made

See How Its Made

The Essence of the Economy (Prentice-Hall Essentials of Management Series)

The Essence of the Economy (Prentice-Hall Essentials of Management Series)

Give Me Liberty! The Story of the Declaration of Independence

Give Me Liberty! The Story of the Declaration of Independence

Rural preparedness for sheep producers

Rural preparedness for sheep producers

Sanford Meisner approach

Sanford Meisner approach

badger with a broken leg

badger with a broken leg

Credit control for a small manufacturer

Credit control for a small manufacturer

The Complete Book of Pan

The Complete Book of Pan

Bibliotheca selectissima diversorum librorum

Bibliotheca selectissima diversorum librorum

Report of the Warren Commission on the Assassinaion of President Kennedy

Report of the Warren Commission on the Assassinaion of President Kennedy

Tully Filmus

Tully Filmus

The Supreme Court of Ireland

The Supreme Court of Ireland

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer by Consensus Development Conference on the Management of Clinically Localized Prostate Cancer (1987 Bethesda (Md.)) Download PDF EPUB FB2

OBJECTIVE: To formulate consensus statements to facilitate physician management strategies for patients with clinically localized prostate cancer (PCa) in Hong Kong by jointly convening a panel of 12 experts from the two local professional organizations representing PCa specialists, who had previously established consensus statements on the management of metastatic PCa for the by: 1.

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer ( Bethesda, Md.). Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Consensus Development Conference on the Management of Clinically Localized Prostate Cancer on JuneAfter a day and a half of presentations by experts and discussion by the audience, a consensus panel drawn from specialists and generalists from the medical profession and related scientific disciplines, clinical investigators, and public representatives considered the evidence.

To formulate consensus statements to facilitate physician management strategies for patients with clinically localized prostate cancer (PCa) in Hong Kong by jointly convening a panel of 12 experts from the two local professional organizations representing PCa specialists, who had previously established consensus statements on the management of metastatic PCa for the by: 1.

Consensus Development Conference on the Management of Clinically Localized Prostate Cancer ( Bethesda, Md.). Approximat new cases of prostate cancer will be diagnosed inof wh are clinically localized, according to the American College of Surgeons, and there are approximat deaths from prostate cancer annually.

It is a common finding at. To formulate consensus statements to facilitate physician management strategies for patients with clinically localised prostate cancer (PCa) in Hong Kong, a panel of 12 experts who previously. High-risk prostate cancer accounts for approximately 15% of all prostate cancer diagnoses.

Patients with high-risk disease have an increased risk of developing biochemical recurrence, metastases, and death from prostate cancer. As the optimal management of high-risk disease in patients with prostate cancer continues to evolve, the contemporary treatment paradigm is moving.

The Advanced Prostate Cancer Consensus Conference (APCCC) provides an update on the current standard of advanced prostate cancer management and a global discussion on questions that occur in daily clinical practice for which there is limited evidence-based data.

The next APCCC is scheduled for August 29 - 31, in Basel, Switzerland. These guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity to facilitate care decisions and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy.

National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, Maryland, JuneNCI Monogr, (7), 01 Jan Cited by: 0 articles | PMID: Review.

The NIH Consensus Development Program represents an important part of the over-all process of assessing research results and their relevance to clinical applications in this country. This Consensus Development Conference on the management of clinically localized prostate cancer is a good example of the process at its best.

Patient summary: The second Advanced Prostate Cancer Consensus Conference APCCC did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer.

These proceedings emanate from the Second Prouts Neck Conference on prostate cancer held on October, the theme of which was treat­ ment, with focus on current issues and future research that is needed to answer critical questions related to optimal management of the various stages of prostate cancer.

The Management of clinically localized prostate cancer. National Institutes of Health (U.S.) National Institutes of Health Consensus Development Conference consensus statement, v. 6, no. Consensus Development Conference on the Management of Clinically Localized Prostate Cancer ( Bethesda, Md.) RCP7 C66 Gay & bisexual men living with prostate cancer: from diagnosis to recovery.

Objective: To provide healthcare providers, patients, and the general public with a responsible assessment of currently available data on the use of active surveillance and other observational management strategies for low-grade, localized prostate cancer.

Participants: A non-U.S. Department of Health and Human Services, nonadvocate member panel representing the fields of cancer. Prostate cancer is an important health problem. More than 40 incident cases of prostate cancer and more than 10 prostate cancer related deaths occur each year in the United Kingdom.1 Prevention, detection, and treatment of localized prostate cancer remain controversial.

Although screening for prostate cancer with serum prostate specific antigen (PSA) testing is not. Overview. A report on the management of clinically localized prostate cancer, the result of the work of the Prostate Cancer Clinical Guidelines Panel of the American Urological Association, has recently been published.

1, 2 The panel conducted an exhaustive and comprehensive survey of all published medical literature relating to the outcomes of treatment of clinically localized prostate cancer. Consensus conference. The management of clinically localized prostate cancer.

JAMA (19):[PUBMED Abstract] Epstein JI, Paull G, Eggleston JC, et al.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol (4):[PUBMED Abstract].

The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times sinceaims to share the knowledge of world experts in prostate cancer management with health care providers worldwide.

Prostate cancer is the most commonly diagnosed cancer in men in the United States (approximatelyin ), nearly 20% of all new cancers, and the second leading cause of cancer-related death (approximat in ).

1 At diagnosis, there is a diverse spectrum of clinical courses that range from indolent features with a negligible.In this review, we summarize contemporary evidence for local treatment strategies, systemic therapy options, and biomarkers in development for the management of high-risk prostate cancer in patients.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. May [Epub].